Research

The Tisch Cancer Institute is a National Cancer Institute-Designated Cancer Center with a mission to accelerate the prevention and treatment of cancer, improving the lives of cancer patients and their families in our communities. To this end, The Tisch Cancer Institute has cultivated collaborative research programs that aim to translate discoveries into new therapies and develop novel prevention and care delivery strategies. We continually give priority to cancers that most affect the patient communities of our catchment area.

With key funding through our National Cancer Institute Cancer Center Support Grant, the Institute fosters a dynamic team of scientists, clinical investigators, and administrators, all of whom create the research infrastructure needed to spur new cancer breakthroughs.

Funding Opportunities

Through our annual Developmental Fund Awards, The Tisch Cancer Institute provides support for pilot projects focused on translational and collaborative research between our cancer research programs.

An independent, dedicated Developmental Fund Award Committee oversees the selection process. On an annual basis, the request for application is created by the Institute’s Developmental Fund Award Committee Chair, Stuart Aaronson, MD, and emailed to current Institute members. The awards support translational and/or epidemiological projects that represent inter- and intra-collaborations between members of The Tisch Cancer Institute, with a requirement that the co-principal investigators of the projects are Institute members.

Prior to a project account being established, the project must comply with internal and regulatory approval processes. Scientific progress is monitored through a mid-year progress report, which is reviewed by the Committee Chair, and a final report is required. No-cost extensions can be requested, but justification is required.  

The Tisch Cancer Institute 2025 Developmental Fund Awardees

Ernesto Guccione and Alessandro Lagana

Ernesto Guccione, PhD (Cancer Mechanisms) and Alessandro Lagana, PhD (Cancer Clinical Investigation)

Dissecting the Impact of DIS3 Mutations in Multiple Myeloma

Carousel Background Image 2

Ernesto Guccione, PhD (Cancer Mechanisms) and Alessandro Lagana, PhD (Cancer Clinical Investigation)

Dissecting the Impact of DIS3 Mutations in Multiple Myeloma

Carousel Background Image 2

Zeynep Gümüş, PhD (Cancer Prevention and Control) and Elvin Wagenblast, PhD (Cancer Mechanisms): Decoding Lymphoid Clonal Hematopoiesis

Mechanisms and Clinical Risk

Ernesto Guccione and Alessandro Lagana

Ernesto Guccione, PhD (Cancer Mechanisms) and Alessandro Lagana, PhD (Cancer Clinical Investigation)

Dissecting the Impact of DIS3 Mutations in Multiple Myeloma

Zeynep Gümüş and Elvin Wagenblast

Zeynep Gümüş, PhD (Cancer Prevention and Control) and Elvin Wagenblast, PhD (Cancer Mechanisms): Decoding Lymphoid Clonal Hematopoiesis

Mechanisms and Clinical Risk

Igor Bado and Yelena Ginzburg

Igor Bado, PhD (Cancer Mechanisms) and Yelena Ginzburg, MD (Cancer Clinical Investigation)

Modulatory Function of Erythroferrone on Metastatic Potential and Anemia in Breast Cancer

Discover the Latest

Contact Us